What other treatments are patients taking while on Remdesivir? Are they also Gilead products?
If B's 3-in-1 only impacts Gilead's Remdesivir, then Gilead should be pursing IP if trials are deemed successful. If the other treatments (anti-inflammatory, antibacterial) are being supplied by other BP's then I say those other PB's should have an interested in IP once we hear of trials success.
There are still a lot of moving parts. Lets get the trial results!